keyword
MENU ▼
Read by QxMD icon Read
search

Drossman

keyword
https://www.readbyqxmd.com/read/29016868/efficacy-and-safety-of-lubiprostone-in-patients-with-opioid-induced-constipation-phase-3-study-results-and-pooled-analysis-of-the-effect-of-concomitant-methadone-use-on-clinical-outcomes
#1
Egilius L H Spierings, Douglas A Drossman, Byron Cryer, M Mazen Jamal, Taryn Losch-Beridon, Shadreck M Mareya, Martin Wang
Objective: The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore the effects of methadone on treatment response. Methods: In the primary study, adults with OIC (fewer than three spontaneous bowel movements [SBMs] per week) were randomized to receive lubiprostone 24 mcg or placebo twice daily for 12 weeks...
July 17, 2017: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/28945206/psychological-distress-and-quality-of-life-in-pediatric-crohn-disease-impact-of-pain-and-disease-state
#2
Robyn Lewis Claar, Miranda A L van Tilburg, Bisher Abdullah, Shelby Langer, Dalia Sherif, William E Whitehead, Douglas A Drossman, Rona L Levy
OBJECTIVES: For patients with Crohn disease (CD), symptom reporting may not coincide with disease state; patients in remission may continue to report symptoms and pain, whereas other patients may be symptom-free despite a flare. This phenomenon has been documented in adults but only recently assessed in pediatric patients. The present study assessed the role of pain reporting and disease state in pediatric patients with CD in understanding psychological distress and quality of life. METHODS: Participants included 116 children and adolescents ages 8 to 18 years with CD who completed self-report questionnaires assessing pain, disease symptoms, depression, anxiety, functional disability, and quality of life...
October 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28932269/evaluation-and-performance-of-a-newly-developed-patient-reported-outcome-instrument-for-diarrhea-predominant-irritable-bowel-syndrome-in-a-clinical-study-population
#3
Leticia Delgado-Herrera, Kathryn Lasch, Bernhardt Zeiher, Anthony J Lembo, Douglas A Drossman, Benjamin Banderas, Kathleen Rosa, Christopher Lademacher, Rob Arbuckle
BACKGROUND: To evaluate the psychometric properties of the newly developed seven-item Irritable Bowel Syndrome - Diarrhea predominant (IBS-D) Daily Symptom Diary and four-item Event Log using phase II clinical trial safety and efficacy data in patients with IBS-D. This instrument measures diarrhea (stool frequency and stool consistency), abdominal pain related to IBS-D (stomach pain, abdominal pain, abdominal cramps), immediate need to have a bowel movement (immediate need and accident occurrence), bloating, pressure, gas, and incomplete evacuation...
September 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28675183/communication-breakdown-between-physicians-and-ibs-sufferers-what-is-the-conundrum-and-how-to-overcome-it
#4
T Jayaraman, R K Wong, D A Drossman, Y Y Lee
Irritable bowel syndrome is a disorder of gut-brain interaction that leads to a significant healthcare burden worldwide. A good physician-patient relationship is fundamental in managing patients who suffer from this poorly understood chronic disease. We highlight possible reasons for breakdown in communication between physicians and irritable bowel syndrome sufferers and suggest possible ways to overcome such pitfalls.
June 2017: Journal of the Royal College of Physicians of Edinburgh
https://www.readbyqxmd.com/read/28544094/development-and-validation-of-the-patient-physician-relationship-scale-among-patients-with-irritable-bowel-syndrome
#5
J E Kurlander, W D Chey, C B Morris, Y J B Hu, R K Padival, S I Bangdiwala, N J Norton, W F Norton, D A Drossman
BACKGROUND: An effective patient-physician relationship (PPR) is essential to the care of patients with irritable bowel syndrome (IBS). We sought to develop and validate an IBS-specific instrument to measure expectations of the PPR. METHODS: We conducted structured focus groups about PPRs with 12 patients with IBS. Qualitative analysis was used to generate a questionnaire (the Patient-Physician Relationship Scale [PPRS]), which was modified with input from content experts and usability testing...
May 22, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28455162/the-episod-study-long-term-outcomes
#6
Peter B Cotton, Qi Pauls, Jamila Keith, Andre Thornhill, Douglas Drossman, April Williams, Valerie Durkalski-Mauldin
BACKGROUND AND AIMS: The EPISOD (Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction) study randomized patients with post-cholecystectomy pain, and little or no objective evidence for biliary obstruction, to sphincterotomy or sham intervention. Results at 1 year showed no benefit for the active treatment. We now report the outcomes at up to 5 years. METHODS: One hundred three patients completing 1 year, and still blinded to treatment allocation, were enrolled and followed by phone every 6 months for a median of 58 months (range, 17-71 months)...
April 25, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28404114/functional-gastrointestinal-disorders-what-s-new-for-rome-iv
#7
Douglas A Drossman
No abstract text is available yet for this article.
September 2016: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28349992/central-neuromodulators-for-treating-functional-gi-disorders-a-primer
#8
REVIEW
W Harley Sobin, Thomas W Heinrich, Douglas A Drossman
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they work, the differences between classes and individual agents, and the various adverse effects are outlined...
May 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28303651/what-s-new-in-rome-iv
#9
REVIEW
J Tack, D A Drossman
The functional gastrointestinal disorders (FGIDs) are the most common disorders seen in Gastroenterology clinical practice. The Rome process has generated consensus definitions of FGIDS, allowing to subdivide patients into diagnostic categories based on the symptom pattern. The Rome IV consensus, presented in 2016, is the most recent update of this diagnostic scheme. This article summarizes the main changes, which include the use of epidemiology-based symptom thresholds to define FGIDs, characterization of FGIDS as disorders of Gut-Brain interaction, and updates of criteria for esophageal disorders, irritable bowel syndrome and Biliary and Sphincter of Oddi disorders based on scientific and technical progress made over the last decade...
September 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28274109/what-is-new-in-rome-iv
#10
REVIEW
Max J Schmulson, Douglas A Drossman
Functional gastrointestinal disorders (FGIDs) are diagnosed and classified using the Rome criteria; the criteria may change over time as new scientific data emerge. The Rome IV was released in May 2016. The aim is to review the main changes in Rome IV. FGIDs are now called disorders of gut-brain interaction (DGBI). Rome IV has a multicultural rather than a Western-culture focus. There are new chapters including multicultural, age-gender-women's health, intestinal microenvironment, biopsychosocial, and centrally mediated disorders...
April 30, 2017: Journal of Neurogastroenterology and Motility
https://www.readbyqxmd.com/read/28238483/psychological-factors-may-play-an-important-role-in-pediatric-crohn-s-disease-symptoms-and-disability
#11
Miranda A L van Tilburg, Robyn Lewis Claar, Joan M Romano, Shelby L Langer, Douglas A Drossman, William E Whitehead, Bisher Abdullah, Rona L Levy
OBJECTIVE: To examine the relative contributions of disease activity and psychological factors to self-reported symptoms and disability in children with Crohn's disease. STUDY DESIGN: Participants (n = 127 children age 8-18 years) completed questionnaires on symptom severity and disability, as well as psychological measures assessing anxiety, depression, pain beliefs and coping. Disease activity was measured by the Pediatric Crohn's Disease Activity Index. Structural equation modeling was used to test the effects of disease activity and psychological factors on symptoms and disability...
May 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/28220776/katie-the-physician-s-perspective-of-a-young-woman-s-illness-experience
#12
Douglas A Drossman
No abstract text is available yet for this article.
April 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28204956/centrally-targeted-pharmacotherapy-for-chronic-abdominal-pain-understanding-and-management
#13
REVIEW
Hans Törnblom, Douglas A Drossman
Chronic abdominal pain has a widespread impact on the individual and the society. Identifying and explaining mechanisms of importance for the pain experience within a biopsychosocial context are central in order to select treatment that has a chance for symptom reduction. With current knowledge of brain-gut interactions, chronic abdominal pain, which mostly appears in functional gastrointestinal disorders, to a large extent involves pain mechanisms residing within the brain. As such, the use of centrally targeted pharmacotherapy as an effective treatment option is obvious in a selected number of patients...
2017: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27970644/translatability-evaluation-of-the-rome-iv-diagnostic-questionnaire-for-adults
#14
A L Crane, A Popielnicki, A D Sperber, D Drossman, O S Palsson, W E Whitehead, E Sweeney, K O'Brien
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27922565/a-perspective-on-brain-gut-communication-the-american-gastroenterology-association-and-american-psychosomatic-society-joint-symposium-on-brain-gut-interactions-and-the-intestinal-microenvironment
#15
Olga C Aroniadis, Douglas A Drossman, Magnus Simren
BACKGROUND: Alterations in brain-gut communication and the intestinal microenvironment have been implicated in a variety of medical and neuropsychiatric diseases. Three central areas require basic and clinical research: (1) how the intestinal microenvironment interacts with the host immune system, central nervous system and enteric nervous system; (2) the role of the intestinal microenvironment in the pathogenesis of medical and neuropsychiatric disease; (3) the effects of diet, prebiotics, probiotics and fecal microbiota transplantation on the intestinal microenvironment and the treatment of disease...
January 17, 2017: Psychosomatic Medicine
https://www.readbyqxmd.com/read/27669680/effects-of-baseline-abdominal-pain-and-bloating-on-response-to-lubiprostone-in-patients-with-irritable-bowel-syndrome-with-constipation
#16
RANDOMIZED CONTROLLED TRIAL
L Chang, W D Chey, D Drossman, T Losch-Beridon, M Wang, P Lichtlen, S Mareya
BACKGROUND: Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both abdominal pain and stool frequency. AIM: In a post hoc analysis, similar criteria were applied to data from two pivotal, phase 3, double-blind, randomised trials of lubiprostone in patients with IBS-C...
November 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27147121/rome-iv-functional-gi-disorders-disorders-of-gut-brain-interaction
#17
Douglas A Drossman, William L Hasler
No abstract text is available yet for this article.
May 2016: Gastroenterology
https://www.readbyqxmd.com/read/27144628/centrally-mediated-disorders-of-gastrointestinal-pain
#18
Laurie Keefer, Douglas A Drossman, Elspeth Guthrie, Magnus Simrén, Kirsten Tillisch, Kevin Olden, Peter J Whorwell
Centrally Mediated Abdominal Pain Syndrome (CAPS), formerly known as Functional Abdominal Pain Syndrome, can be distinguished from other functional GI disorders by its strong central component and relative independence from motility disturbances. CAPS is a result of central sensitization with disinhibition of pain signals rather than increased peripheral afferent excitability. A newly described condition, Narcotic Bowel Syndrome (NBS)/Opioid-Induced GI Hyperalgesia, is characterized by the paradoxical development of or increases in abdominal pain associated with continuous or increasing dosages of opioids...
February 19, 2016: Gastroenterology
https://www.readbyqxmd.com/read/27144624/biopsychosocial-aspects-of-functional-gastrointestinal-disorders
#19
Lukas Van Oudenhove, Michael D Crowell, Douglas A Drossman, Albena D Halpert, Laurie Keefer, Jeffrey M Lackner, Tasha B Murphy, Bruce D Naliboff, Rona L Levy
In this paper, we provide a general framework for understanding the functional gastrointestinal disorders (FGID) from a biopsychosocial perspective. More specifically, we provide an overview of the recent research on how the complex interactions of environmental, psychological, and biological factors contribute to the development and maintenance of the FGID. We emphasize that considering and addressing all these factors is a conditio sine qua non for appropriate treatment of these conditions. First, we provide an overview of what is currently known about how each of these factors - the environment, including the influence of those in an individual's family, the individual's own psychological states and traits, and the individual's (neuro)physiological make-up - interact to ultimately result in the generation of FGID symptoms...
February 18, 2016: Gastroenterology
https://www.readbyqxmd.com/read/27144617/functional-gastrointestinal-disorders-history-pathophysiology-clinical-features-and-rome-iv
#20
Douglas A Drossman
Functional gastrointestinal disorders (FGIDs), the most common diagnoses in gastroenterology are recognized by morphological and physiological abnormalities that often occur in combination including motility disturbance, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota and altered central nervous system processing. Research on these gut-brain interaction disorders is based on using specific diagnostic criteria. The Rome Foundation has played a pivotal role in creating diagnostic criteria thus operationalizing the dissemination of new knowledge in the field of FGIDs...
February 19, 2016: Gastroenterology
keyword
keyword
100000
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"